Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism

Variability among individuals in their therapeutic response to psychotropic drugs and in susceptibility to adverse effects is considerable. Pharmacogenetics addresses the contribution of genetic factors to this variability. An important focus of interest in pharmacogenetics has been on candidate genes that play a role in susceptibility to the antipsychotic drug-induced adverse effect, tardive dyskinesia (TD). Four published studies have reported an association between a serine (ser) to glycine (gly) polymorphism in exon 1 of the dopamine D3 receptor gene (DRD3) and TD; three failed to replicate this finding and one found an insignificant trend. We examined the association in a pooled sample of 780 patients (317 with TD and 463 without TD) drawn from 6 research centers, who were divided into 8 groups based on their population origin. The analysis employed stepwise logistic regression so as to allow confounding effects of group, age, and gender to be taken into account. TD was significantly associated with DRD3 gly allele carrier status (x2=4.46, df 1, p = .04) and with DRD3 genotype (x2=6.62, df 2, p = .04) over and above the effect of group. Similar positive effects were observed when controlling for age and gender (x2=5.02, df 1, p = .02 for gly allele carrier status; x2 = 7.51, df 2, p = .002 for genotype). Examining abnormal involuntary movement scores as a continuous variable, we found that patients homozygous for the gly allele had significantly higher scores than ser-gly heterozygotes (p = .006) or ser-ser homozygotes (p < .0001). We also performed a meta-analysis that included, besides the groups in the combined analysis, three other published studies on DRD3 and TD. The Mantel-Haenszel pooled odds ratio for DRD3 gly allele carrier status increasing susceptibility to TD was 1.33 (95% CI 1.04–1.70, p = .02); the cumulative pooled estimate showed an odds ratio of 1.52 (95% CI 1.08–1.68, p < .0001). These findings support a small but significant contribution of the DRD3 ser9gly polymorphism to TD susceptibility that is demonstrable over and above population effects and the effect of age and gender on the phenotype.

[1]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[2]  G. Simpson,et al.  A rating scale for tardive dyskinesia , 1979, Psychopharmacology.

[3]  M. J. Arranz,et al.  Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response , 1998, Schizophrenia Research.

[4]  Fabio Macciardi,et al.  Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia , 1999, Neuropsychopharmacology.

[5]  W. Tang,et al.  Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients , 2001, Journal of Neural Transmission.

[6]  M. P. Turpin,et al.  Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. , 1996, Biochemical and biophysical research communications.

[7]  D. Stein,et al.  Treatment of schizophrenia in low-income countries. , 1999, The international journal of neuropsychopharmacology.

[8]  M. Catalano.  The challenges of psychopharmacogenetics. , 1999, American journal of human genetics.

[9]  N. Risch.  Searching for genetic determinants in the new millennium , 2000, Nature.

[10]  B. Lerer,et al.  Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility , 2000, Psychopharmacology.

[11]  E H Cook,et al.  Pharmacogenetics and the serotonin system: initial studies and future directions. , 2000, European journal of pharmacology.

[12]  B. Lerer,et al.  Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia , 2002, Molecular Psychiatry.

[13]  M. Martres,et al.  Chromosomal localization of the human D3 dopamine receptor gene , 1991, Human Genetics.

[14]  K. Weiss,et al.  How many diseases does it take to map a gene with SNPs? , 2000, Nature Genetics.

[15]  R. Baldessarini,et al.  Changes in prevalence, severity, and recovery in tardive dyskinesia with age. , 1980, Archives of general psychiatry.

[16]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.

[17]  M. Dahl,et al.  Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. , 1995, Journal of clinical psychopharmacology.

[18]  E. Smeraldi,et al.  Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and Persistence , 1993, Neuropsychopharmacology.

[19]  T. White,et al.  Human Leucocyte Antigens and Tardive Dyskinesia , 1991, British Journal of Psychiatry.

[20]  M. Asai,et al.  Search for a Susceptibility Locus to Tardive Dyskinesia , 1997 .

[21]  B. Lerer,et al.  Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia , 2001, Molecular Psychiatry.

[22]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.

[24]  M. Martres,et al.  Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders , 1992 .

[25]  B. Lerer,et al.  Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. , 2002, The international journal of neuropsychopharmacology.

[26]  K. Hornik,et al.  Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. , 1999, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.

[27]  H. Meltzer,et al.  Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine , 2000, Biological Psychiatry.

[28]  M. Rietschel,et al.  Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder , 2000, Molecular Psychiatry.

[29]  K. Hsiao,et al.  Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia , 1997, Biological Psychiatry.

[30]  D. Greenberg.  Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association , 1993 .

[31]  J. Kane,et al.  Familial occurrence of tardive dyskinesia. , 1981, The Journal of clinical psychiatry.

[32]  T. Terao,et al.  Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics , 1998, Schizophrenia Research.

[33]  J. Kane,et al.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 , 1982, Archives of general psychiatry.

[34]  V. Steen,et al.  Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. , 2000, The international journal of neuropsychopharmacology.

[35]  D. Clayton,et al.  Statistical modeling of interlocus interactions in a complex disease: rejection of the multiplicative model of epistasis in type 1 diabetes. , 2001, Genetics.

[36]  T. Terao,et al.  Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients , 1999, Psychiatry Research.

[37]  P. Phillips.  The language of gene interaction. , 1998, Genetics.

[38]  D. Jeste,et al.  Gender differences in tardive dyskinesia: a critical review of the literature. , 1992, Schizophrenia bulletin.

[39]  S. Kasper,et al.  Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia , 1998, Schizophrenia Research.

[40]  D. Cooper,et al.  The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences , 1992, Human Genetics.

[41]  D. S. Zahm,et al.  On the significance of subterritories in the “accumbens” part of the rat ventral striatum , 1992, Neuroscience.

[42]  E. Tan,et al.  Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor , 2001, Biological Psychiatry.

[43]  R. Yassa,et al.  Familial tardive dyskinesia. , 1981, The American journal of psychiatry.

[44]  J. Waddington,et al.  The Expression of Schizophrenia, Affective Disorder and Vulnerability to Tardive Dyskinesia in an Extensive Pedigree , 1988, British Journal of Psychiatry.

[45]  B. Lerer,et al.  Interactive effect of cytochrome P450 17α-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia , 2002, Biological Psychiatry.

[46]  J. Lieberman,et al.  Tardive dyskinesia: prevalence, incidence, and risk factors. , 1985, Psychopharmacology. Supplementum.

[47]  J. Pritchard,et al.  Use of unlinked genetic markers to detect population stratification in association studies. , 1999, American journal of human genetics.

[48]  S. Tsai,et al.  Association between the Ser9Gly Polymorphism of the Dopamine D3 Receptor Gene and Tardive Dyskinesia in Chinese Schizophrenic Patients , 2001, Neuropsychobiology.

[49]  J. Lieberman,et al.  Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia , 2001, Molecular Psychiatry.

[50]  D. Pickar,et al.  Pharmacogenomics of psychiatric disorders. , 2001, Trends in pharmacological sciences.

[51]  H. Rosengarten,et al.  Possible genetic factors underlying the pathophysiology of tardive dyskinesia , 1994, Pharmacology Biochemistry and Behavior.

[52]  J. Kane,et al.  Research diagnoses for tardive dyskinesia. , 1982, Archives of general psychiatry.

[53]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[54]  B. Lerer,et al.  Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia , 1999, Molecular Psychiatry.

[55]  E. Smeraldi,et al.  A genetic study of Tardive Dyskinesia in an Italian population of chronic schizophrenics , 1996 .

[56]  L. Penrose,et al.  THE CORRELATION BETWEEN RELATIVES ON THE SUPPOSITION OF MENDELIAN INHERITANCE , 2022 .

[57]  E. Yunis,et al.  Immunogenetic markers in chlorpromazine-induced tardive dyskinesia , 1986, Journal of Neuroimmunology.

[58]  D. Jeste,et al.  Understanding and Treating Tardive Dyskinesia , 1982 .

[59]  F. Youssef,et al.  Familial psychosis and vulnerability to tardive dyskinesia. , 1989, International clinical psychopharmacology.

[60]  K. Hornik,et al.  Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients , 1999, European Neuropsychopharmacology.

[61]  S. Cichon,et al.  Pharmacogenetics of schizophrenia. , 2000, American journal of medical genetics.

[62]  Jane S. Paulsen,et al.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. , 1995, Archives of general psychiatry.

[63]  E. Tan,et al.  Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese. , 2000, American journal of medical genetics.

[64]  S. Paige,et al.  HLA antigens in tardive dyskinesia , 1990, Journal of Neuroimmunology.

[65]  J. Idle,et al.  Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype , 1997, British Journal of Psychiatry.

[66]  J. Lieberman,et al.  Prospective study of tardive dyskinesia in the elderly: rates and risk factors. , 1998, The American journal of psychiatry.

[67]  M. Rietschel,et al.  Dopamine D3 receptor variant and tardive dyskinesia , 2000, European Archives of Psychiatry and Clinical Neuroscience.

[68]  M. Catalano.  PSYCHIATRIC GENETICS '99 The Challenges of Psychopharmacogenetics , 1999 .

[69]  O. Andreassen,et al.  Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients , 1997, Psychopharmacology.

[70]  M. Rietschel,et al.  Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. , 2001, American journal of medical genetics.

[71]  S. Leucht,et al.  Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[72]  M Masellis,et al.  A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia , 2000, Molecular Psychiatry.

[73]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[74]  Li Wan Po,et al.  Pharmacogenetics and psychopharmacotherapy , 2000, Journal of clinical pharmacy and therapeutics.

[75]  R. Fisher.  XV.—The Correlation between Relatives on the Supposition of Mendelian Inheritance. , 1919, Transactions of the Royal Society of Edinburgh.

[76]  T. Shinkai,et al.  Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia: Relation to Tardive Dyskinesia , 2000, Neuropsychopharmacology.

[77]  V. Steen,et al.  Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients , 1997, Molecular Psychiatry.